JCP
IBB icon

Jabre Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Jabre Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-15,000
Closed -$1.14M – 128
2013
Q4 		$1.14M Buy
+15,000
New +$1.06M 0.09% 109

Other funds holding IBB

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Jabre Capital Partners's IBB Position: Q1 2014 in Review

Jabre Capital Partners sold out of iShares Biotechnology ETF (IBB) in Q1 2014, closing a stake of 15,000 shares — an estimated $1.14M sold.

Jabre Capital Partners first reported a position in IBB in Q4 2013 and held it in 1 quarter. The position peaked at $1.14M in Q4 2013. 288 funds tracked by Wall St. Rank hold IBB as of Q1 2014.

  • Jabre Capital Partners reported no remaining iShares Biotechnology ETF position as of Q1 2014 after selling out during the quarter.
  • Jabre Capital Partners sold 15,000 iShares Biotechnology ETF shares in Q1 2014, an estimated $1.14M.
  • Jabre Capital Partners first reported a position in iShares Biotechnology ETF in Q4 2013 and held it in 1 quarter.
  • Jabre Capital Partners's iShares Biotechnology ETF position peaked at $1.14M in Q4 2013.
  • 288 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2014.

Based on Jabre Capital Partners's 13F filing for Q1 2014, filed 15 May 2014.